The 7 Wall Street analysts covering Eikon Therapeutics, Inc. hold a median 12-month price target of $28 — +414.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 28 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Eikon Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (61): Smaller than most of the companies we track.
Volatility (1): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on EIKN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +414.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 16 Oct 2026 | HC Wainwright & Co. | Initiates | Buy | $23 |
| 14 Aug 2026 | Wedbush | Maintains | Underperform | $5.00 → $4.00 |
| 14 Aug 2026 | Wedbush | Maintains | Underperform | — |
| 12 May 2026 | Wedbush | Maintains | Underperform | — |
| 12 May 2026 | Wedbush | Maintains | Underperform | $7.00 → $5.00 |
| 31 Mar 2026 | Wedbush | Reiterates | Underperform | — |
| 2 Mar 2026 | B of A Securities | Initiates | Buy | — |
| 2 Mar 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 2 Mar 2026 | JP Morgan | Initiates | Overweight | — |
| 2 Mar 2026 | Mizuho | Initiates | Outperform | — |
| 2 Mar 2026 | Morgan Stanley | Initiates | Overweight | — |
| 26 Feb 2026 | Wedbush | Initiates | Underperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
EIKN appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 83% of US stocks
Cheaper than 80% of US stocks
Cheaper than 63% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 91% of US stocks
Higher than 7% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Eikon Therapeutics, Inc. has a market value of $300.1M and an enterprise value of $21.4M.
Revenue in the twelve months to 30 June 2026: $0.0.
Net income over the same four quarters: −$322.2M.
Free cash flow in the twelve months to 30 June 2026: −$259.2M.
Trailing P/E: −0.9×; forward P/E: −0.8× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Eikon Therapeutics, Inc. employs 384 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Eikon Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Eikon Therapeutics announced that updated EIK1001 data from the TeLuRide-005 study were presented at the 2026 European Society for Medical Oncology Congress in Madrid.
Why it matters — The presentation provides EIKN watchers with an update on clinical data for EIK1001.
Eikon Therapeutics announced that it presented initial and updated data for EIK1003 and initial data for EIK1004 and EIK1005 at the 2026 ESMO Congress in Madrid.
Why it matters — The presentations provide EIKN watchers with an update on data from the company’s PARP1-selective and WRN helicase programs.
Eikon Therapeutics announced that full-text abstracts covering its four clinical candidates will be presented at the 2026 ESMO Congress, beginning October 23 in Madrid. The presentations include updated and initial clinical data across studies of EIK1001, EIK1003, EIK1004 and EIK1005.
Why it matters — The abstracts will provide updates on clinical development across Eikon’s pipeline, including studies in lung, prostate and other advanced cancers.
Eikon Therapeutics announced that it submitted an IND application to the FDA to evaluate EIK1006 for advanced metastatic prostate cancer.
Why it matters — The submission marks a regulatory step toward evaluating EIK1006 in prostate cancer.
Eikon Therapeutics, Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with a full transcript of the presentation published by Seeking Alpha. The presentation provides an account of the company's remarks at the conference.
Why it matters — Eikon watchers can review the transcript of the company's presentation at a major investment conference for insight into its positioning and updates.
The 7 Wall Street analysts covering Eikon Therapeutics, Inc. have a median 12-month price target of $28, with estimates ranging from $4 to $32. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Eikon Therapeutics, Inc., 6 rate it a Buy, 0 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Eikon Therapeutics, Inc. 1 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Eikon Therapeutics, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (61 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +414.0% from the last close, and Ticker Nerd's factor model ranks Eikon Therapeutics, Inc. 1 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Eikon Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EIKN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $32 over the next 12 months.
Eikon Therapeutics Inc. is a late-stage clinical biopharmaceutical company focused on developing innovative medicines for serious unmet medical needs.
The most recent item we track (GlobeNewsWire, 26 Oct 2026): "Eikon Therapeutics Presents Updated EIK1001 Data from TeLuRide-005 at the European Society for Medical Oncology Congress". Eikon Therapeutics announced that updated EIK1001 data from the TeLuRide-005 study were presented at the 2026 European Society for Medical Oncology Congress in Madrid.
Eikon Therapeutics Inc. is a late-stage clinical biopharmaceutical company focused on developing innovative medicines for serious unmet medical needs. Eikon Therapeutics Inc. concentrates primarily on oncology, advancing a pipeline of product candidates designed to target difficult-to-treat cancers and other solid tumors. Its current programs include antibody-free and small-molecule therapies that act on pathways such as immune activation, DNA repair, and androgen receptor signaling. The company also uses a proprietary drug discovery platform that combines super-resolution microscopy, automation, data science, machine learning, and software engineering to study protein behavior in living cells and guide target identification. Headquartered in Millbrae, California, Eikon Therapeutics Inc. plays a role in the biopharmaceutical market by translating advanced biology and engineering into clinical-stage therapeutic development.
CEO Dr. Roger M. Perlmutter M.D., Ph.D. · 384 employees · United States · https://eikontx.com
